British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...

The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

Miels said the new plan includes “changing our marketing mix to focus on segments who are tougher to activate.” Making Shields part of the marketing mix has enabled GSK to win mainstream media ...

GSK's specialty medicines segment showed strong performance, growing over 20% due to successful new launches. Additionally, GSK is currently undervalued, trading at £16.1, significantly below the ...

Shares of GSK PLC GSK inched down 0.97% to £16.39 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.57% to 8,240.97.

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares opened today at p1,644. ...

Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...

GSK has returned Wednesday morning with fresh phase 2 data that show new formulations of the vaccine “demonstrated positive A and B strain immune responses relative to standard of care in both ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK ... Firms that develop new drugs, particularly those that operate in the biotechnology industry, don't do well in a tough ...

The company's strategic focus on innovation, particularly in R&D, is evident from its investments in new vaccines and medicines, combining scientific focus on the immune system with advanced ...

(Reuters) -British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to ...